• Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing and regional commercialization for this $600 million market
• VT-1953 for malignant fungating wounds remains Vyome's flagship program and primary capital allocation priority

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.